Regulatory Review
Reviewed by PeptidePrescriber Editorial Team.
Last reviewed: April 17, 2026Source review date: April 17, 2026
Primary sources
The July 23-24, 2026 PCAC meeting matters because FDA has already identified peptide-related bulk drug substances it plans to discuss for possible inclusion on the 503A bulks list. It does not, by itself, finalize the outcome.
July 23 agenda
- BPC-157-related bulk drug substances for ulcerative colitis
- KPV-related bulk drug substances for wound healing and inflammatory conditions
- TB-500-related bulk drug substances for wound healing
- MOTs-C-related bulk drug substances for obesity and osteoporosis
July 24 agenda
- Emideltide (DSIP)-related bulk drug substances for opioid withdrawal, chronic insomnia, and narcolepsy
- Semax-related bulk drug substances for cerebral ischemia, migraine, and trigeminal neuralgia
- Epitalon-related bulk drug substances for insomnia
What to watch
- Watch whether FDA framing changes from transitional removal language toward a clearer forward path on nominated 503A bulks-list inclusion.
- Do not treat the meeting notice as an authorization shortcut in consent language, staff training, or pharmacy-facing communications.
- Prepare dated internal scripts, staff explanations, and chart-note language so your practice can respond quickly if FDA posture shifts again around the meeting.
Starter Pack
Keep regulatory updates aligned with your patient-facing workflow.
Use the starter pack when you want the consent packet, implementation checklist, and regulatory quick reference to stay synchronized with current FDA posture.